The implementation of immune checkpoint inhibitors (ICIs), specifically programmed cell death protein 1 (PD-1)/ PD receptor ligand-1 (PD-L1) antibodies, has significantly improved the progression-free-survival (PFS) and overall survival (OS) rates of patients with advanced non-small cell lung carcinoma (NSCLC) [1, 2]. Here, PDCD1 is linked to non-small cell lung carcinoma.